COPD

These mental health outcomes were seen among those with self-reported COPD and asthma, though not among individuals with objective diagnoses based on spirometry.

In this Q&A discussion, Bhatt discusses the recent news of dupilumab’s supplemental Biologics License Application for COPD patients with type 2 inflammation, as well as its significance.

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.

These data, given sustainability targets in healthcare, may be considered by clinicians and by patients discussing DPIs.

This data from the NOTUS trial is set to be submitted to the FDA alongside the phase 3 BOREAS trial data later in the year.

This new data on dupilumab demonstrates the drug’s potential usefulness in treating type 2 inflammation, a role which is central to respiratory diseases including COPD.

This portion of Mosher’s interview featured a discussion about the future of respiratory care following the updates on the guidelines for pulmonary rehabilitation delivery.

During this segment of his interview, Mosher discussed center-based pulmonary rehabilitation versus telerehabilitation and other elements from the updated guidelines.

In this discussion, Dr. Mosher shared several key insights on the recently updated clinical practice guidelines for pulmonary rehabilitation delivery.

This new data indicates opportunities which may have been missed for initiation of fracture prevention for elderly individuals treated with oral corticosteroids.

"Our research is unique in its attempt to describe a high-need, high-cost patient population who might benefit from increased monitoring or intervention," Dr. Ann Cameron says.

"High-risk patients are more likely to experience comorbid conditions and are more likely to use COPD medications and oxygen, reflecting a higher disease burden," Dr. Ann Cameron explains.

“We all know that exacerbations are the most costly disease impact of COPD,” study investigator Dr. Charlie Strange says.

Amid mass poor air quality exposure due to ongoing Canadian wildfires, Lungcast reviews air quality index, signs and symptoms of acute and long-term poor air exposure, high-risk patient populations, and the concerning future of particle pollution exposure.

Data indicates that addressing mood disorders in patients not only improves mood symptoms but also demonstrates positive effects on certain cardiac events, suggesting benefits for both mental and physical well-being.

Key opinion leaders at ATS 2023 urge physicians to treat more than just symptoms in patients with COPD and consider mood disorders and cardiac comorbidities.

In an interview at ATS 2023, Dr. Rutland stresses the importance of studying the immune system's response to various diseases, emphasizing the potential impact of pipeline molecules.

Though still not in abundance on the market, ICS/LAMA/LABA triple-therapy single inhaler treatment options are becoming more valued for COPD exacerbation and comorbid disease risk.

Dr. Rutland emphasizes the importance of understanding cellular communication and its potential to manipulate disease processes for patient benefit, including the observed link between ILD, inflammation, scarring, and pulmonary hypertension.

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

An analysis of the COPDGene Study presented at ATS 2023 suggests presence of mucus plugs in medium- to large-sized airways were associated with an increased risk of mortality in adjusted models.

At West Penn Hospital, the harmonica program, currently in the pilot phase, aims to demonstrate its benefits in improving respiratory symptoms, reducing exacerbations, and enhancing patients' quality of life.

"Playing the harmonica has a therapeutic effect because of the pursed lip breathing technique it requires," Dr. Becky Jordan says in an interview.

On the latest Lungcast, Kalhan reviewed a 2018 paper he and colleagues penned on the need to establish phenotypes of chronic lung disease progression—such as what cardiology has done with LDL-C for heart attacks.

Insomnia shows associations with higher rates of outpatient visits, hospitalizations, and fills for medications, longer hospital length of stay, and higher hospitalization costs.